The clinical guidelines for the diagnosis and management of LAM issued by the American Thoracic Society (ATS) and the Japanese Respiratory Society (JRS) recommended that patients with characteristic chest HRCT changes and the abnormal elevation of serum vascular endothelial growth factor-D (VEGF-D) levels can be diagnosed without lung biopsy [6]. The gene discussed is VEGFD; the disease is lymphangioleiomyomatosis.